Sangamo Therapeutics (SGMOQ) EBIT Margin (2010 - 2025)
Sangamo Therapeutics (SGMOQ) posted quarterly EBIT Margin of 268.51% for Q4 2025, up 13134.0% year-over-year from N/an in Q4 2024, and up 95.61% quarter-over-quarter from 6119.28% in Q3 2025.
Sangamo Therapeutics (SGMOQ) EBIT Margin (2010 - 2025) Analysis & Trends
Sangamo Therapeutics' EBIT Margin history runs 16 years deep, the most recent figure standing at 268.51% for Q4 2025.
- In Q4 2025, EBIT Margin rose 13134.0% year-over-year to 268.51%; the TTM figure through Dec 2025 stood at 306.53% (down 12332.0% YoY), while the FY2025 annual figure was 306.53%, down 12665.0% from the prior year.
- EBIT Margin for Q4 2025 stood at 268.51%, up from 6119.28% in the prior quarter.
- The five-year high for EBIT Margin was 21.52% in Q3 2024, with the low at 10712.27% in Q1 2024.
- The 5-year median for EBIT Margin is 205.44% (2022), against an average of 1790.54%.
- The sharpest annual moves came in 2024 and 2025: EBIT Margin tumbled 1072368 bps in 2024, then jumped 1031932 bps in 2025.
- Sangamo Therapeutics' EBIT Margin stood at 142.57% in 2021, then tumbled by 43 bps to 203.42% in 2022, then tumbled by 1394 bps to 3039.13% in 2023, then jumped by 87 bps to 399.85% in 2024, then jumped by 33 bps to 268.51% in 2025.
- Business Quant data shows SGMOQ's EBIT Margin at 268.51% in Q4 2025, 6119.28% in Q3 2025, and 97.54% in Q2 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -268.51% |
| Sep 30, 2025 | -6,119.28% |
| Jun 30, 2025 | -97.54% |
| Mar 31, 2025 | -460.28% |
| Dec 31, 2024 | -399.85% |
| Sep 30, 2024 | 21.52% |
| Jun 30, 2024 | -10,416.85% |
| Mar 31, 2024 | -10,712.27% |
| Dec 31, 2023 | -3,039.13% |
| Sep 30, 2023 | -1,132.24% |
| Jun 30, 2023 | -1,807.93% |
| Mar 31, 2023 | 11.42% |
| Dec 31, 2022 | -203.42% |
| Sep 30, 2022 | -207.46% |
| Jun 30, 2022 | -155.67% |
| Mar 31, 2022 | -160.32% |
| Dec 31, 2021 | -142.57% |
| Sep 30, 2021 | -169.58% |
| Jun 30, 2021 | -174.73% |
| Mar 31, 2021 | -176.19% |